Related Content
- FDA studies effectiveness, benefits of long-term smoking-cessation therapy
- GSK Consumer Healthcare applauds FDA's workshop on NRT products
- Study: Significant decline in pack-a-day smokers
- New Nicorette ads underscore process of kicking the habit
- Pharmacies should get out of tobacco-selling, into smoking-cessation game
SCHLIEREN, Switzerland — Cytos Biotechnology will regain rights to an experimental vaccine against nicotine addiction that it had licensed to Novartis, Cytos said Wednesday.
The company said that Novartis would discontinue the project, known as NIC002. Cytos granted Novartis a license for NIC002 in 2007, but phase-2 trial results in October 2009 indicated that the vaccine spurred the development of nicotine-specific antibodies in patients, but did not increase smoking cessation.
The companies will continue collaborating on the development of CAD106, a treatment for patients with Alzheimer's disease.
Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.
